Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Risk Assessment and Treat Compliance in Hypertension Education Trial (RATCHET)

This study has been completed.
Sponsor:
Collaborators:
University of Western Ontario, Canada
The Physicians' Services Incorporated Foundation
Information provided by:
Lawson Health Research Institute
ClinicalTrials.gov Identifier:
NCT00694239
First received: June 6, 2008
Last updated: June 29, 2011
Last verified: June 2011
  Purpose
The RATCHET study assesses if patient knowledge of estimated cardiovascular risk at current and recommended target blood pressure levels improves compliance in the management of hypertension.

Condition Intervention
Hypertension
Dyslipidemia
Behavioral: Knowledge of Cardiovascular Risk Assessment

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evaluation of the Effect of Cardiovascular Risk Assessment in Treatment Compliance in Hypertension

Resource links provided by NLM:


Further study details as provided by Lawson Health Research Institute:

Primary Outcome Measures:
  • Medication Compliance [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Patient perception of cardiovascular risk [ Time Frame: 1 year ]
  • Pilot Feasibility Study [ Time Frame: 1 year ]
  • Blood Pressure [ Time Frame: 1 year ]
  • Cholesterol Level [ Time Frame: 1 year ]
  • Framingham Risk Score (stroke and coronary artery disease) [ Time Frame: 1 year ]

Estimated Enrollment: 100
Study Start Date: May 2007
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: B
Standard Care
Experimental: A
Risk Assessment plus standard care
Behavioral: Knowledge of Cardiovascular Risk Assessment
Knowledge of Cardiovascular Risk Assessment and risk reduction at target BP, reviewed every 3-6 months.

  Eligibility

Ages Eligible for Study:   30 Years to 84 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Essential hypertension (new diagnosis or established diagnosis) meeting criteria for pharmacologic therapy as defined by current guidelines

Exclusion Criteria:

  • Lack of written informed consent
  • Previous myocardial infarction
  • Previous stroke
  • Congestive heart failure
  • Stage 3 or greater chronic kidney disease
  • Pregnancy
  • Usage of medication bubble/blister package
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00694239

Locations
Canada, Ontario
University of Western Ontario
London, Ontario, Canada, N6A 5A5
Sponsors and Collaborators
Lawson Health Research Institute
University of Western Ontario, Canada
The Physicians' Services Incorporated Foundation
Investigators
Principal Investigator: Bryan J Har, MD University of Western Ontario, Canada
Principal Investigator: George K Dresser, PhD, MD University of Western Ontario, Canada
  More Information

Additional Information:
Responsible Party: George Dresser, University of Western Ontario
ClinicalTrials.gov Identifier: NCT00694239     History of Changes
Other Study ID Numbers: R-07-053
13014E ( Other Identifier: REB )
Study First Received: June 6, 2008
Last Updated: June 29, 2011

Keywords provided by Lawson Health Research Institute:
hypertension
compliance

Additional relevant MeSH terms:
Hypertension
Dyslipidemias
Vascular Diseases
Cardiovascular Diseases
Lipid Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on April 21, 2017